Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations

K. Pal, Sumanta; E. Rosenberg, Jonathan; Hoffman‐Censits, Jean; Berger, Raanan; I. Quinn, David; D. Galsky, Matthew; Wolf, Juergen; Dittrich, Christian; Keam, Bhumsuk; Delord, Jean‐Pierre; H.M. Schellens, Jan; Gravis, Gwénaëlle; Médioni, Jacques; Maroto, Pablo; Sriuranpong, Virote; Charoentum, Chaiyut; A. Burris, Howard; Grünwald, Viktor; P. Petrylak, Daniel; N. Vaishampayan, Ulka; Gez, Eliahu; De Giorgi, Ugo; Lee, Jae‐Lyun; Voortman, Jens; Gupta, Sumati; Sharma, Sunil; Mortazavi, Amir; J. Vaughn, David; Isaacs, Randi; Parker, Katie; Chen, Xueying; Yu, Kun; Porter, Dale; Graus Porta, Diana; F. Bajorin, Dean

doi:10.1158/2159-8290.cd-18-0229

Public

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

Published in Cancer Discovery • May 30, 2018

Authors:

Sumanta K. Pal

Jonathan E. Rosenberg

Jean Hoffman‐Censits

Abstract

Abstract BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received ...

Subject

Medicine

Metastatic Urothelial Carcinoma

Hyperphosphatemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!